Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
An 8-week Randomized, Double Blind, Multi-center, Placebo-controlled Study To Evaluate The Efficacy, Safety And Tolerability Of Pregabalin ( 300mg/Day ) Using A Fixed Dosing Schedule In The Treatment Of Subjects With Postherpetic Neuralgia ( Phn )
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Listed as NCT01455428, this PHASE4 trial focuses on Postherpetic Neuralgia ( PHN ) and remains completed. Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc., it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Feb 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE4
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Dec 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Chengdu/wuhou D, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Jinan, China , Nanjing, China , Shanghai, China , Shenzhen, China , Suzhou, China and 2 more locations